Literature DB >> 15326255

Sustained remission of CIDP associated with Evans syndrome.

Hans Knecht1, Michael Baumberger, Aurelio Tobòn, Andreas Steck.   

Abstract

A patient with chronic inflammatory demyelinating polyneuropathy (CIDP) developed Evans syndrome (hemolytic anemia/thrombocytopenia) 17 months after onset of symptoms despite different immunomodulatory treatments. A therapeutic approach with the chimeric monoclonal anti-CD20 antibody rituximab induced substantial improvement of CIDP and hematologic recovery. The patient remains in sustained remission 17 months after completion of therapy. Rituximab may represent a successful therapy in otherwise refractory CIDP.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15326255     DOI： 10.1212/01.wnl.0000134606.50529.c7

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 2.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

Review 3.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Inna Kleyman; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

4.  Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases.

Authors:  Daniele Velardo; Nilo Riva; Ubaldo Del Carro; Francesca Bianchi; Giancarlo Comi; Raffaella Fazio
Journal:  J Neurol       Date:  2017-03-23       Impact factor: 4.849

5.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

6.  Neurological Involvement in Childhood Evans Syndrome.

Authors:  Thomas Pincez; Bénédicte Neven; Hubert Ducou Le Pointe; Pascale Varlet; Helder Fernandes; Albane Gareton; Guy Leverger; Thierry Leblanc; Hervé Chambost; Gérard Michel; Marlène Pasquet; Frédéric Millot; Olivier Hermine; Alexis Mathian; Marie Hully; Hélène Zephir; Mohamed Hamidou; Jean-Marc Durand; Yves Perel; Judith Landman-Parker; Fréderic Rieux-Laucat; Nathalie Aladjidi
Journal:  J Clin Immunol       Date:  2019-01-22       Impact factor: 8.317

Review 7.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 8.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 9.  Treatment of dys-immune neuropathies.

Authors:  Eduardo Nobile-Orazio
Journal:  J Neurol       Date:  2005-04       Impact factor: 4.849

Review 10.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.